Scenario:
A large multinational organization is rolling out a company-wide AI governance initiative. To build awareness and support adoption, they are evaluating different ways to train employees and stakeholders across departments, including legal, technical, marketing, and customer-facing roles.
Which of the following typical approaches is a large organization least likely to use to responsibly train stakeholders on AI terminology, strategy and governance?
Scenario:
An organization wants to leverage its existing compliance structures to identify AI-specific risks as part of an ongoing data governance audit.
Which of the following compliance-related controls within an organization is most easily adapted to identify AI risks?
You are the chief privacy officer of a medical research company that would like to collect and use sensitive data about cancer patients, such as their names, addresses, race and ethnic origin, medical histories, insurance claims, pharmaceutical prescriptions, eating and drinking habits and physical activity.
The company will use this sensitive data to build an Al algorithm that will spot common attributes that will help predict if seemingly healthy people are more likely to get cancer. However, the company is unable to obtain consent from enough patients to sufficiently collect the minimum data to train its model.
Which of the following solutions would most efficiently balance privacy concerns with the lack of available data during the testing phase?
You are part of your organization’s ML engineering team and notice that the accuracy of a model that was recently deployed into production is deteriorating.
What is the best first step address this?
During the development of semi-autonomous vehicles, various failures occurred as a result of the sensors misinterpreting environmental surroundings, such as sunlight.
These failures are an example of?
When monitoring the functional performance of a model that has been deployed into production, all of the following are concerns EXCEPT?
CASE STUDY
Please use the following answer the next question:
A mid-size US healthcare network has decided to develop an Al solution to detect a type of cancer that is most likely arise in adults. Specifically, the healthcare network intends to create a recognition algorithm that will perform an initial review of all imaging and then route records a radiologist for secondary review pursuant Agreed-upon criteria (e.g., a confidence score below a threshold).
To date, the healthcare network has taken the following steps: defined its Al ethical principles: conducted discovery to identify the intended uses and success criteria for the system: established an Al governance committee; assembled a broad, crossfunctional team with clear roles and responsibilities; and created policies and procedures to document standards, workflows, timelines and risk thresholds during the project.
The healthcare network intends to retain a cloud provider to host the solution and a consulting firm to help develop the algorithm using the healthcare network's existing data and de-identified data that is licensed from a large US clinical research partner.
The most significant risk from combining the healthcare network’s existing data with the clinical research partner data is?
Which of the following is the least relevant consideration in assessing whether users should be given the right to opt out from an Al system?
What is the best method to proactively train an LLM so that there is mathematical proof that no specific piece of training data has more than a negligible effect on the model or its output?
The most important factor in ensuring fairness when training an Al system is?